Apogee therapeutics announces first patient dosed in part b of phase 2 apex trial of apg777 in patients with moderate-to-severe atopic dermatitis

Enrollment of part a completed ahead of schedule and exceeded enrollment target with 123 patients enrolled part a 16-week proof-of-concept data anticipated in mid-2025 san francisco and boston, feb. 03, 2025 (globe newswire) -- apogee therapeutics, inc., (nasdaq: apge), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (i&i) markets, including for the treatment of atopic dermatitis (ad), asthma, chronic obstructive pulmonary disease (copd), eosinophilic esophagitis (eoe) and other i&i indications, today announced the first patient has been dosed in the part b portion of the phase 2 apex clinical trial of apg777 in patients with moderate-to-severe ad, as well as enrollment completion in the part a portion of the trial. “enrollment for the phase 2 part a trial of apg777 surpassed the approximately 110 patient target ahead of schedule, driven by strong patient and investigator enthusiasm, underscoring the potential of apg777 to address the need for safe, effective treatment options that reduce injection burden and provide better disease control for patients with ad and other i&i conditions,” said carl dambkowski, m.d.
APG Ratings Summary
APG Quant Ranking